I pancreas- cancerstudiet (kombination med gemcitabin) var incidensen af ILD - lignende hændelser 2, 5% i gruppen med Tarceva plus gemcitabin versus 0, 4% i gruppen behandlet med placebo plus gemcitabin.
In the pancreatic cancer study in combination with gemcitabine, the incidence of ILD-like events was 2.5% in the Tarceva plus gemcitabine group versus 0.4% in the placebo plus gemcitabine treated group.